Date: 2012-03-07
Type of information: R&D agreement
Compound:
Company: Sanofi (France) The Centre for Genomic Regulation (Centre de Regulació Genòmica - CRG) (Spain)
Therapeutic area: Rare diseases - Genetic diseases - Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: genetic diseases and rare diseases
Details: The Centre for Genomic Regulation (Centre de Regulació Genòmica - CRG) and Sanofi have announced a research collaboration on shared research programmes using state-of-the-art experimental platforms and computational and bioinformatics approaches, in the field of computational biology, medical genetics and epigenetics, with special emphasis in genetic and rare diseases.
Within the framework of the agreement, the CRG and Sanofi have already initiated a first set of projects to discover innovative therapeutic approaches for infectious diseases, develop novel delivery systems using synthetic biology, decipher disease-relevant cellular trans-differentiation pathways, and identify original targets from unexploited genomic transcription mechanisms.
These four projects will bring added value to basic research by offering a better understanding of disease for pathologies such as tuberculosis and cancer, and also by helping to develop new therapeutic solutions for their treatment.
\"We recognise that in order to deliver on our promise to address patients’ needs, we need to tap into and enable innovation inside and outside our walls. Our new relationship with the CRG demonstrates our commitment to work with partners on conditions with unmet and growing medical needs”, said Dr Maya Said, Sanofi R&D, Vice President for Strategy, Science Policy & External Innovation.
Further highly innovative collaborative projects will be selected and launched within the 3-year period of the agreement.
Financial terms:
Latest news:
